Adalimumab (Humira) in Combination with Methotrexate is Efficacious for Treatment in RA Patients

Weinblatt et al (Arthritis Rheum 48:35, 2003)) evaluate the efficacy and safety of adalimumab in combination with methotrexate in patients with active rheumatoid arthritis (results from the ARMADA Trial).

In a 24-week placebo-controlled trial, 271 with active rheumatoid arthritis (RA) despite treatment with methotrexate were radomized to receive adalimumab injections (20 mg, 40 mg, or 80 mg subcutaneously) or placebo. ACR 20, 50, and 70 responses were statistically greater in patients treated with adulimumab and methotrexate compared with patients treated with placebo and methotrexate. Data was presented at the EULAR 2001 annual meeting. (see data)